R＆D協同分析-以生技公司為例

Abstract

Biotech industry is a knowledge-intensive, technical-intensive, and capital-intensive industry. It is also acknowledged as one of the most potential industry in 21st century. With the increasing competitive, many biotech companies and pharmaceutical companies use the concept of collaborative development to reduce investment the cost and risk. The biotech company will co-develop with collaborative partners during the new drug development process. In order to increasing the chance of success, they will monitor the risks and maintain the relationship continuously during the development process. This research uses three tools to analyze the collaborative development in the case of a biotech company. These tools are object-oriented coordination structure, collaboration lifecycle analysis, and collaboration maturity grids. We use the object-oriented coordination structure to analyze the collaborative interactions between the biotech company and pharmaceutical company, and give the blueprint of the project execution. Using the collaborative lifecycle analysis, we can find out the risks and provide the suggestions to decrease and avoid the negative impacts of the risk during the development process. The collaboration maturity grids can be used to determine the maturity degree of the collaborative capability of the biotech company. Finally, we analyze the information collected from the case company to summarize the important guidelines to further help enterprises co-develop the new product in the future.